quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:30:52·21d
SECFiling
Viatris Inc. logo

SEC Form DEF 14A filed by Viatris Inc.

VTRS· Viatris Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • VTRS
    Viatris Inc.
    Health Care

Recent analyst ratings

  • Feb 9UpdateUBS$18.00
  • Jan 16UpdateArgus$15.00
  • Dec 9UpdateBarclays$15.00
  • Oct 15UpdateTruist$15.00
  • Jun 6UpdateGoldman$10.00
  • Jul 19UpdateJefferies$15.00

Related

  • INSIDER7d
    SEC Form 4 filed by Le Goff Corinne
  • PR10d
    Viatris to Report First Quarter 2026 Financial Results on May 7, 2026
  • PR13d
    Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
  • SEC21d
    SEC Form DEFA14A filed by Viatris Inc.
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Viatris Inc.
  • INSIDER30d
    SEC Form 4 filed by Campbell Paul
  • SEC31d
    SEC Form 144 filed by Viatris Inc.
  • PR31d
    Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022